Déri, S.; Hartai, T.; Virág, L.; Jost, N.; Labro, A.J.; Varró, A.; Baczkó, I.; Nattel, S.; Ördög, B.
A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5. Pharmaceuticals 2022, 15, 1550.
https://doi.org/10.3390/ph15121550
AMA Style
Déri S, Hartai T, Virág L, Jost N, Labro AJ, Varró A, Baczkó I, Nattel S, Ördög B.
A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5. Pharmaceuticals. 2022; 15(12):1550.
https://doi.org/10.3390/ph15121550
Chicago/Turabian Style
Déri, Szilvia, Teodóra Hartai, László Virág, Norbert Jost, Alain J. Labro, András Varró, István Baczkó, Stanley Nattel, and Balázs Ördög.
2022. "A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5" Pharmaceuticals 15, no. 12: 1550.
https://doi.org/10.3390/ph15121550
APA Style
Déri, S., Hartai, T., Virág, L., Jost, N., Labro, A. J., Varró, A., Baczkó, I., Nattel, S., & Ördög, B.
(2022). A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5. Pharmaceuticals, 15(12), 1550.
https://doi.org/10.3390/ph15121550